Shares of CureVac (NASDAQ:CVAC - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $3.00, but opened at $3.08. CureVac shares last traded at $2.97, with a volume of 116,822 shares.
Wall Street Analyst Weigh In
Separately, JMP Securities reissued a "market outperform" rating and issued a $16.00 price target on shares of CureVac in a report on Friday, February 14th.
Read Our Latest Stock Analysis on CVAC
CureVac Price Performance
The company has a market cap of $667.16 million, a P/E ratio of 5.42 and a beta of 2.53. The stock has a 50-day simple moving average of $3.38 and a 200 day simple moving average of $3.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new position in shares of CureVac in the 3rd quarter valued at $35,000. Two Sigma Advisers LP acquired a new position in CureVac in the fourth quarter worth about $48,000. Jump Financial LLC acquired a new stake in CureVac during the fourth quarter valued at approximately $55,000. D. E. Shaw & Co. Inc. acquired a new position in shares of CureVac in the 4th quarter worth approximately $66,000. Finally, Barclays PLC bought a new position in shares of CureVac during the 3rd quarter worth approximately $67,000. 17.26% of the stock is owned by institutional investors.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Articles
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
